Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives approval for use of Symbicort

AstraZeneca receives approval for use of Symbicort

2nd March 2009

AstraZeneca has received approval for the use of Symbicort to treat conditions including chronic bronchitis and emphysema.

The decision was based on results from two clinical trials which found that the drug improved lung function within five minutes of the first dose and led to sustained improvement over the duration of the investigation.

It has now been authorised for the twice-daily maintenance treatment of airflow obstruction in sufferers of chronic obstructive pulmonary disease (COPD).

Since June 2007, a pressurised metered-dose inhaler version of the remedy has been available for the long-term maintenance of asthma in those aged 12 and over.

Dr Howard Hutchinson, chief medical officer of AstraZeneca, explained that every day millions of people suffer from the symptoms and effects of COPD.

He commented that the latest approval will mean that “patients have a new treatment option that can deliver long-term lung function improvement and daily symptom control, together with a rapid onset of action”.

The pharmaceutical company is active in over 100 countries and employs over 67,000 staff.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.